Copyright
©The Author(s) 2015.
World J Diabetes. Aug 10, 2015; 6(9): 1092-1096
Published online Aug 10, 2015. doi: 10.4239/wjd.v6.i9.1092
Published online Aug 10, 2015. doi: 10.4239/wjd.v6.i9.1092
Figure 2 Selected outcome trials in type 2 diabetes with a focus on di-peptidyl peptidase-4 inhibitor studies, and their results, in the context of the duration of intervention and the study population’s diabetes duration and baseline cardiovascular risk.
CV: Cardiovascular; UKPDS: United Kingdom Prospective Diabetes Study; VADT: Veterans affairs diabetes trial.
- Citation: Johansen OE. Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World J Diabetes 2015; 6(9): 1092-1096
- URL: https://www.wjgnet.com/1948-9358/full/v6/i9/1092.htm
- DOI: https://dx.doi.org/10.4239/wjd.v6.i9.1092